Vessl’s Medical technology belongs to the field of regenerative medicine and incorporates both cell therapy and gene therapy. Vessl uses vascular endothelial cells to activate genes for therapeutic purposes by growing new compatible vectors/grafts through grafting.

Main product (technology) :

  1. Multi-gene angiogenic growth vectors/grafts (MGAs) for peripheral arterial disease MGAs are formed using endothelial cells activated by the Ang-1 gene in combination with smooth muscle cells activated by the VEGF gene.
  2. Multigene grafts (MGG) for dialysis access. MGG is formed by grafting endothelial cells + polymers activated by the fibulin-5 gene.